Why I think Avita Medical shares are a buy in 2020

Avita Medical Limited (ASX: AVH) experienced over 700% share price growth in 2019, resulting in a market cap of $1.66 billion – skyrocketing it into the ASX 200.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

With an impressive run as one of the top performing Australian stocks of 2019, Avita Medical Limited (ASX: AVH) experienced over 700% share price growth last year, resulting in a market cap of $1.66 billion (at the time of writing) and earning it a place in the S&P/ASX 200 (INDEXASX: XJO).

The company has made a name for itself primarily through the development of its revolutionary RECELL technology.

What is all the hype about RECELL?

RECELL is a regenerative medicine with undeniable results, contributing to the company's recent success. It is currently used primarily in the treatment of second and third-degree burns with impressive efficacy. The technology has shown to be significantly more effective than the current split-thickness skin grafts method which leaves a noticeable scar on the site of procedure. RECELL allows for treatment with a drastic decrease in life-long scars. Comparing the amount of donor skin required for burn victim treatments, studies have shown the RECELL system has a 97.5% reduction in the donor's skin requirement for second-degree burns, and a 32% reduction for third-degree.

The company reports that RECELL has been used more than 8,000 times to date commercially, with no observed safety signals. Doctors reportedly found that using RECELL was significantly less painful for patients while providing results faster.

Avita Medical is a global operation with RECELL approved in the United States, Europe, China, and Australia. They are currently in the process of being approved to market in Japan, with JPMDA approval expected in 2020. The company has proactively secured a collaboration with COSMOTEC to market and distribute RECELL treatments in Japan after approval.

In addition, RECELL is being researched to treat paediatric scalds and soft tissue reconstruction by the end of Q1 2020, and repigmentation for vitiligo by Q3 2020. Completing these milestones provides Avita Medical with avenues into markets beyond burn treatments. The company currently values the opportunities of these markets at over US$1.1 billion.

What about Avita Medical's financial performance? 

After only one year of RECELL being used in the US, which is the technology's largest market in terms of sales, Avita Medical is well positioned to continue its growth phase into the future.

Total revenue for the year amounted to $9,974,801 with a 56% increase in sales from Q2 to Q3. These sales were maintained into Q4 of the year.

Following this trend, Avita has reported growth in its new accounts and trained burn surgeons every quarter, with a total of 60 cumulative accounts and 166 cumulative physicians.

The company is also well financed with $124.6 million cash in bank and low debt (current ratio of 5.5 and a debt-to-equity ratio of 0.2%), as of 31 December 2019. Total cash outflows for the next quarter are estimated to be $12.3 million. Having a significant surplus of cash provides Avita with the necessary cash flow to continue progressing through its development pipeline without needing to raise funds.

For these reasons, I think 2020 provides significant growth opportunities for Avita Medical Limited and investors.

Motley Fool contributor Jordan Liu owns shares of Avita Medical Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »